Lecanemab + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Preclinical Alzheimer's Disease
Conditions
Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease
Trial Timeline
Jul 14, 2020 → Jan 16, 2031
NCT ID
NCT04468659About Lecanemab + Placebo
Lecanemab + Placebo is a phase 3 stage product being developed by Eisai for Preclinical Alzheimer's Disease. The current trial status is active. This product is registered under clinical trial identifier NCT04468659. Target conditions include Preclinical Alzheimer's Disease, Early Preclinical Alzheimer's Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04468659 | Phase 3 | Active |